![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
794kB |
![[thumbnail of Supporting Information]](https://mdc-test.eprints-hosting.org/style/images/fileicons/application_msword.png) |
MS Word (Supporting Information)
1MB |
| Item Type: | Article |
|---|---|
| Title: | B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity |
| Creators Name: | Bennett, J.L., Pittock, S.J., Paul, F., Kim, H.J., Irani, S.R., O'Connor, K.C., Patterson, K.R., Smith, M.A., Gunsior, M., Mittereder, N., Rees, W.A., Cimbora, D. and Cree, B.A.C. |
| Abstract: | This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20(+) and CD27(+) B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed. |
| Source: | Annals of Clinical and Translational Neurology |
| ISSN: | 2328-9503 |
| Publisher: | Wiley |
| Date: | 2024 |
| Official Publication: | https://doi.org/10.1002/acn3.52171 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
